electroCore

ECOR

Market cap $53.1M

ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS): A Narrative Review," in Frontiers in Neuroscience. The article was authored by Peter S. Staats, MD, MBA, Chief Medical Officer of electroCore, and Justyna Blake, Senior Director of Medical Affairs at electroCore.

electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026.

ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the review article, "Without getting under your skin: non-invasive stimulation activates the vagus nerve," has been accepted for publication in Frontiers in Neuroscience.

ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub being held at the Bellagio Resort & Casino in Las Vegas, NV. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one investor meetings throughout the conference.

electroCore NASDAQ: ECOR Interim President and CFO Joshua Lev said the bioelectronic technology company is focused on expanding its non-invasive vagus nerve stimulation platform across federal health care, commercial insurance channels and consumer wellness markets.

ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in JAMA Network Open titled, “Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial.

ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA.   Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.

electroCore, Inc. (ECOR) Q1 2026 Earnings Call Transcript

electroCore, Inc. (ECOR) came out with a quarterly loss of $0.59 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.47 per share a year ago.